This work provides a comprehensive and novel perspective on HDAC3’s dual role in tumor progression and immunotherapy, highlighting its therapeutic potential both as a standalone target and as a critical component of combination therapies aimed at overcoming resistance and broadening the scope of immunotherapy. The gene discussed is HDAC3; the disease is neoplasm.